The cover for issue 29 of Oncotarget features Figure 2, "Categorisation of samples analysed," from Laes, et al.
- OncoDNA treatment recommendation followed in 60% of cases
- 93% of treatment decisions were made based on a holistic approach combining next generation sequencing (NGS) and multiple biomarker analysis provided by OncoDNA
- 27% of late-stage patients treated with OncoDNA-recommended therapies had overall survival less than 12 months, compared to a typical average of no more than six months
Gosselies, Belgium - April 17, 2018: OncoDNA ("OncoDNA or "the Company"), the healthcare technology company that collates and translates complex cancer biomarker data to make precision medicine a reality, is pleased to announce the publication of a study in the journal Oncotarget evaluating the utility of OncoDNA's comprehensive biomarker analysis and interpretation services in clinical settings.
The study, published online today and titled "The clinical impact of using complex molecular profiling strategies in routine oncology practice", found that combining advanced, comprehensive testing of cancer biomarkers with OncoDNA's proprietary cancer treatment knowledge database can enable oncologists to make better treatment decisions for their patients. This is because OncoDNA's testing combines immunohistochemistry, next generation sequencing (NGS), and other tests including inherited heart condition testing, DNA methylation, and microsatellite instability (MSI) testing, rather than the industry standard of NGS testing alone.
Full press release - https://www.oncotarget.com/news/pr/oncodna-announces-publication-of-peer-reviewed-study-in-oncotarget-assessing-the-utility-of-its-unique-biomarker-analysis-and-interpretation-platform-in-clinical-decision-making/
DOI - https://doi.org/10.18632/oncotarget.24757
Full text - https://www.oncotarget.com/article/24757/text/
Correspondence to - Jean-François Laes - jf.laes@oncodna.com
Keywords - molecular profiling, solid tumour, precision medicine, next-generation sequencing, therapeutic decision making in oncology
About Oncotarget
Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology.
To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:
SoundCloud - https://soundcloud.com/oncotarget
Facebook - https://www.facebook.com/Oncotarget/
Twitter - https://twitter.com/oncotarget
Instagram - https://www.instagram.com/oncotargetjrnl/
YouTube - https://www.youtube.com/c/OncotargetYouTube/
LinkedIn - https://www.linkedin.com/company/oncotarget
Pinterest - https://www.pinterest.com/oncotarget/
Reddit - https://www.reddit.com/user/Oncotarget/
Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls
Media Contact
MEDIA@IMPACTJOURNALS.COM
18009220957
